LAQV REQUIMTE
My LAQV

(Chemical) Bonding is what makes life possible

Lucília Saraiva

Back
lucilia.saraiva@ff.up.pt
+351 220428584
Webpages
CV
Lab webpage

Research group
Chemistry and Bioactivity

Position
Academic Staff

ORCID0000-0002-9531-4939
Researcher IDD-4897-2013
Ciência ID0A11-3A2E-8FE1
Degree in Pharmaceutical Sciences (1998) at Universidade do Porto - Faculdade de Farmácia, and PhD in Pharmacology (2003) at Universidade do Porto - Faculdade de Farmácia. She is Assistant Professor at Universidade do Porto - Faculdade de Farmácia and Principal Investigator at REQUIMTE - LAQV Porto. Works in the area(s) of Medical and Health Sciences with emphasis on Pharmacology, Oncobiology, and Microbial Biotechnology. Keywords: Experimental Therapeutics; Targeted therapy; Cancer; p53 family proteins; BRCA; Yeast model.

Representative Publications

DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties
10.1002/1878-0261.12051
Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction
10.1002/med.21393
p53 family interactions and yeast: together in anticancer therapy
10.1016/j.drudis.2016.02.007
Reactivation of wild-type and mutant p53 by tryptophanol-derived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule
A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins
10.1016/j.phrs.2015.03.006
A yeast model of the Parkinson's disease-associated protein Parkin
10.1016/j.yexcr.2015.02.018
Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction
10.1016/j.ejps.2014.10.006
A selective activator of protein kinase C discovered using yeast
LRRK2, but not pathogenic mutants, protects against H2O2 stress depending on mitochondrial function and endocytosis in a yeast model
10.1016/j.bbagen.2014.02.015
Potential small-molecule activators of caspase-7 identified using yeast-based caspase-3 and-7 screening assays
10.1016/j.ejps.2013.12.017
Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity
10.1111/febs.12552
Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach
10.1016/j.bcp.2013.01.032
alpha-Mangostin and Gambogic Acid as Potential Inhibitors of the p53-MDM2 Interaction Revealed by a Yeast Approach
10.1021/np400049j
Discovery of a New Inhibitor of P53/MDM2 Interaction Using a Yeast Target-based Screening Strategy
Discovery of a small-molecule protein kinase C delta-selective activator with promising application in colon cancer therapy
10.1038/s41419-017-0154-9
The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding
10.3390/ijms19041184
Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity
10.1016/j.ejmech.2018.07.037
p53 and glucose metabolism: an orchestra to be directed in cancer therapy
10.1016/j.phrs.2018.03.015
Improving anticancer activity towards colon cancer cells with a new p53-activating agent
10.1111/bph.14468
New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma
10.1016/j.canlet.2019.01.014
SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma
10.3390/cancers11081151
BRCA1/P53: Two strengths in cancer chemoprevention
10.1016/j.bbcan.2020.188339
p73: From the p53 shadow to a major pharmacological target in anticancer therapy
10.1016/j.phrs.2020.105245
Structural and Drug Targeting Insights on Mutant p53
10.3390/cancers13133344
A selective p53 activator and anticancer agent to improve colorectal cancer therapy.
10.1016/j.celrep.2021.108982
Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance
10.3390/cancers13071648